整体活检Gleason评分3+4=7且最高评分3+4=7或>3+4=7的前列腺癌患者特征与结局
研究基于ERSPC队列1031例前列腺癌活检,按WHO/ISUP 2014标准复核,比较整体Gleason评分3+4=7患者中最高评分3+4=7(HI=OV)与最高评分>3+4=7(HI>OV)的临床病理特征及结局。结果显示HI>OV者年龄、PSA、阳性活检数、肿瘤累及百分比、Gleason 4百分比及筛状/导管内生长更高(均P<0.05),但生化复发无统计学差异。结论支持使用整体Gleason评分进行临床决策。
要点
- 整体Gleason评分3+4=7患者中16%最高评分>3+4=7
- 最高评分>3+4=7者临床病理特征更差但生化复发无差异
- 临床决策可使用整体Gleason评分以避免过度治疗
核心结论
- 在整体活检Gleason评分3+4=7患者中,最高评分>3+4=7者临床病理特征更差,但临床结局无统计学差异,支持使用整体Gleason评分进行临床决策。
研究设计与样本
- 基于欧洲前列腺癌筛查随机研究(ERSPC)的前列腺癌活检,按WHO/ISUP 2014指南复核,共纳入1031例。
主要发现
- 370例患者整体Gleason评分为3+4=7,其中60例(16%)至少一个活检核心Gleason评分为4+3=7或4+4=8。
- 最高评分>3+4=7者年龄、PSA水平、阳性活检数、肿瘤累及百分比、Gleason 4百分比及筛状或导管内生长均高于最高评分3+4=7者(均P<0.05)。
- 多变量Cox回归分析(纳入PSA、阳性活检百分比和肿瘤累及百分比)显示,两组根治性前列腺切除术后(P=0.52)或放疗后(P=0.35)生化复发无统计学差异。
临床怎么用
- 对于整体活检Gleason评分3+4=7的前列腺癌患者,临床决策可依据整体Gleason评分而非最高Gleason评分,可能避免过度治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Prostate cancer heterogeneity and multifocality might result in different Gleason scores (GS) at individual biopsy cores. According to World Health Organisation/International Society of Urologic Pathology (WHO/ISUP) guidelines, the GS in each biopsy core should be recorded with optional reporting of overall GS for the entire case. We aimed to compare the clinicopathological characteristics and outcome of men with overall biopsy GS 3 + 4 = 7 with highest GS 3 + 4 = 7 (HI = OV) to those with highest GS > 3 + 4 = 7 (HI > OV). METHODS AND RESULTS: Prostate cancer biopsies from the European Randomised Study of Screening for Prostate Cancer (ERSPC) were revised according to WHO/ISUP 2014 guidelines (n = 1031). In total, 370 patients had overall GS 3 + 4 = 7, 60 of whom (16%) had had at least one biopsy core with GS 4 + 3 = 7 or 4 + 4 = 8. Men with higher GS than 3 + 4 (HI > OV) in any of the cores had higher age, prostate-specific antigen (PSA) level, number of positive biopsies, percentage tumour involvement, percentage Gleason grade 4 and cribriform or intraductal growth (all P < 0.05) than those with GS 3 + 4 = 7 at highest (HI = OV). In multivariable Cox regression analysis, including PSA, percentage positive biopsies and percentage tumour involvement, biochemical recurrence-free survival after radical prostatectomy (P = 0.52) or radiotherapy (P = 0.35) was not statistically different between both groups. CONCLUSION: Among patients with overall GS 3 + 4 = 7, those with highest GS > 3 + 4 = 7 had worse clinicopathological features, but clinical outcome was not statistically significant. Therefore, the use of overall GS instead of highest GS for clinical decision-making is justified, potentially preventing overtreatment in prostate cancer patients.
引用
- Verhoef EI, Kweldam CF, Kümmerlin IP, et al. Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7. Histopathology. 2018. PMID: 29094386. doi:10.1111/his.13427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。